Pharmacology - Research Publications
Permanent URI for this collectionhttps://kr.cup.edu.in/handle/32116/111
Browse
5 results
Search Results
Item Understanding the neuronal synapse and challenges associated with the mitochondrial dysfunction in mild cognitive impairment and Alzheimer's disease(Elsevier B.V., 2023-09-13T00:00:00) Verma, Harkomal; Gangwar, Prabhakar; Yadav, Anuradha; Yadav, Bharti; Rao, Rashmi; Kaur, Sharanjot; Kumar, Puneet; Dhiman, Monisha; Taglialatela, Giulio; Mantha, Anil KumarSynaptic mitochondria are crucial for maintaining synaptic activity due to their high energy requirements, substantial calcium (Ca2+) fluctuation, and neurotransmitter release at the synapse. To provide a continuous energy supply, neurons use special mechanisms to transport and distribute healthy mitochondria to the synapse while eliminating the damaged mitochondria from the synapse. Along the neuron, mitochondrial membrane potential (?) gradient exists and is highest in the somal region. Lower ? in the synaptic region renders mitochondria more vulnerable to oxidative stress-mediated damage. Secondly, mitochondria become susceptible to the release of cytochrome c, and mitochondrial DNA (mtDNA) is not shielded from the reactive oxygen species (ROS) by the histone proteins (unlike nuclear DNA), leading to activation of caspases and pronounced oxidative DNA base damage, which ultimately causes synaptic loss. Both synaptic mitochondrial dysfunction and synaptic failure are crucial factors responsible for Alzheimer's disease (AD). Furthermore, amyloid beta (A?) and hyper-phosphorylated Tau, the two leading players of AD, exaggerate the disease-like pathological conditions by reducing the mitochondrial trafficking, blocking the bi-directional transport at the synapse, enhancing the mitochondrial fission via activating the mitochondrial fission proteins, enhancing the swelling of mitochondria by increasing the influx of water through mitochondrial permeability transition pore (mPTP) opening, as well as reduced ATP production by blocking the activity of complex I and complex IV. Mild cognitive impairment (MCI) is also associated with decline in cognitive ability caused by synaptic degradation. This review summarizes the challenges associated with the synaptic mitochondrial dysfunction linked to AD and MCI and the role of phytochemicals in restoring the synaptic activity and rendering neuroprotection in AD. � 2023 Elsevier B.V. and Mitochondria Research Society. All rights reserved.Item Targeting Mitochondria as a Novel Disease-Modifying Therapeutic Strategy in Cancer(Springer Singapore, 2022-09-28T00:00:00) Bhatti, Gurjit Kaur; Pahwa, Paras; Gupta, Anshika; Sidhu, Inderpal Singh; Navik, Uma Shanker; Reddy, P. Hemachandra; Bhatti, Jasvinder SinghMitochondria are essential for the metabolism of energy, regulation of apoptosis, and cell signaling. Overproduction of reactive oxidation species (ROS) in mitochondria is one of the indications of cancer cells. Moreover, this boosts the proliferation of cancerous cells by causing genomic instability and altering gene expressions. Mitochondrial and nuclear DNA mutations caused by oxidative damage impair the mechanism of oxidative phosphorylation and can lead to more mitochondrial ROS output, genome instability, and cancer development. The classic approach to target mitochondria of cancerous cells with novel targeted therapeutics helps in targeting the mitochondrial apoptotic proteins and changing energy metabolism. A key benefit of selective drug delivery is that it reduces the drug�s toxicity and increases specificity. A better understanding of the mitochondrial role in tumor growth will help design more therapeutic agents with better selectivity. � Springer Nature Singapore Pte Ltd. 2022.Item Mitochondria-targeted drug delivery systems for the effective treatment of neurodegenerative disorders(Elsevier, 2022-03-18T00:00:00) Khare, Vaishali; Gupta, Surbhi; Bisht, Preeti; Garabadu, DebapriyaMitochondria are known to be the powerhouse of the cell. Its dysfunction leads to several alterations in cellular physiology. Mitochondrial dysfunction is a well-documented process in the pathophysiology of neurodegeneration and neurodegenerative disorders. The interplay between mitochondrial dysfunction and oxidative stress is well suggested in the pathophysiology of neurodegenerative disorders. The activation of autophagy is also well established along with the mitochondrial impairment in neurodegenerative disorders. The relationship between mitochondrial dysfunction and excitotoxicity is also well established in the pathophysiology of neurodegenerative disorders. Enhanced apoptosis and necrosis is well established along with mitochondrial dysfunction in the pathophysiology of neurodegenerative disorders. Several synthetic and herbal drugs have been established in the management of mitochondrial dysfunction-induced neurodegenerative disorders. Little information is available about the formulations of the established mitochondria-targeted drugs in the management of neurodegenerative disorders. Therefore, critical attention is required in the development of mitochondria-targeted drug delivery systems for therapeutic and diagnostic applications in neurodegenerative disorders. � 2022 Elsevier Inc. All rights reserved.Item Targeting Mitochondria as a Novel Disease-Modifying Therapeutic Strategy in Cancer(Springer Nature, 2022-01-31T00:00:00) Bhatti, Gurjit Kaur; Pahwa, Paras; Gupta, Anshika; Navik, Uma Shanker; Reddy, P. Hemachandra; Bhatti, Jasvinder SinghMitochondria are important for the metabolism of energy, regulation of apoptosis and cell signaling. Overproduction of reactive oxidation species (ROS) in mitochondria is one of the indications of cancer cells; moreover, this boosts the proliferation of cancerous cells by causing genomic instability and altering gene expressions. Mitochondrial and nuclear DNA mutations, caused by oxidative damage which impairs the mechanism of oxidative phosphorylation, can lead to more mitochondrial ROS output, genome instability, and the development of the cancer. Classic approach to target mitochondria of cancerous cells with novel-targeted therapeutics helps in targeting the mitochondrial apoptotic proteins and changing energy metabolism. Key benefit of selective drug delivery is it reduces the toxicity of drug and increases specificity. Better understanding of mitochondrial role in tumor growth will help to design more therapeutic agents with better selectivity. � Springer Nature Singapore Pte Ltd. 2022.Item Quercetin Exhibits ?7nAChR/Nrf2/HO-1-Mediated Neuroprotection Against STZ-Induced Mitochondrial Toxicity and Cognitive Impairments in Experimental Rodents(Springer, 2021-09-23T00:00:00) Singh, Niraj Kumar; Garabadu, DebapriyaThe objective of the present study was to investigate the ?7nAChR-mediated Nrf2-dependant protective activity against streptozotocin (STZ)-induced brain mitochondrial toxicity in Alzheimer�s disease (AD)-like rats. STZ (3�mg/kg) was injected through an intracerebroventricular route to induce AD-like dementia. Repeated Quercetin (50�mg/kg, i.p.) administration attenuated cognitive impairments in the STZ-challenged animals during Morris water-maze and Y-maze tests. Quercetin significantly mitigated the STZ-induced increase in cholinergic dysfunction, such as the increase in acetylcholinesterase activity, decrease in acetylcholine level, and activity of choline acetyltransferase, and increase in amyloid-beta aggregation and mitochondrial toxicity in respect of mitochondrial bioenergetics, integrity, and oxidative stress in memory-challenged rat hippocampus, prefrontal cortex and, amygdala. Further, Quercetin significantly attenuated STZ-induced reduction in the ?7nAChRs and HO-1 expression levels in the selected rat brain regions. On the contrary, trigonelline (10�mg/kg, i.p.) and methyllycaconitine (2�mg/kg; i.p.) abolished the neuroprotective effects of Quercetin against STZ-induced behavioral, molecular, and biochemical alterations in the AD-like animals. Hence, Quercetin exhibits ?7nAChR/Nrf2/HO-1-mediated neuroprotection against STZ-challenged AD-like animals. Thus, Quercetin could be considered as a potential therapeutic option in the management of AD. Graphical Abstract: [Figure not available: see fulltext.] � 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.